Canada Reconsiders Comparative Clinical Trials Requirements for Biosimilars

On June 10, 2025, Health Canada initiated a public consultation on proposed revisions to its Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs. A notable update is the proposal to remove the requirement for comparative clinical efficacy and safety trials for biosimilars in Canada….
By: Stikeman Elliott LLP